Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-14

Study Completion Date

2020-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective multi-site randomized sham-controlled crossover feasibility study evaluating tolerability and efficacy of noninvasive peripheral nerve stimulation (NPNS) for patients with moderate-severe primary Restless Legs Syndrome (RLS). Response to NPNS investigational device was compared to sham control in a 2x2 crossover design such that subjects were assigned to receive 2 weeks of NPNS and 2 weeks of sham, in randomized order.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of RLS/WED Symptoms Through Sensory Counter-stimulation

NCT03249779

Restless Legs Syndrome Willis-Ekbom Disease

COMPLETED NA

Combined Effects of Near-Infrared Light and Vibration on Diabetic Patients With Restless Leg Syndrome

NCT07308080

Restless Leg Syndrome (RLS)

NOT_YET_RECRUITING NA

RESTIFFIC™ Foot Wrap Reduces Moderate to Severe Restless Leg Syndrome

NCT02386423

Restless Leg Syndrome

COMPLETED NA

Neuromuscular Electrical Stimulation Via the Peroneal Nerve Reduces Muscle Soreness Following Intermittent Exercise

NCT02018211

Delayed Onset Muscle Soreness

COMPLETED NA

Neuromuscular Electrical Stimulation Cycling

NCT03208439

Stroke

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Restless Legs Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Noninvasive Peripheral Nerve Stimulation

NPNS device programmed to deliver active stimulation.

Group Type ACTIVE_COMPARATOR

Noctrix Health NPNS device v1.0 - Active

Intervention Type DEVICE

Wearable device programmed to deliver electrical stimulation to peripheral nerves of the lower limbs.

Sham control

NPNS device programmed to deliver sham stimulation.

Group Type SHAM_COMPARATOR

Noctrix Health NPNS device v1.0 - Sham

Intervention Type DEVICE

Wearable device programmed to deliver sham stimulation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Noctrix Health NPNS device v1.0 - Active

Wearable device programmed to deliver electrical stimulation to peripheral nerves of the lower limbs.

Intervention Type DEVICE

Noctrix Health NPNS device v1.0 - Sham

Wearable device programmed to deliver sham stimulation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has moderate-severe RLS symptoms as defined by a score of 15 or greater points on IRLS.
* RLS symptoms are primarily noticeable in the subject's lower legs and/or feet.
* Subject reports having a medical diagnosis of primary idiopathic restless legs syndrome (RLS) or Willis-Ekbom Disorder (WED) OR Investigator has diagnosed the subject with primary idiopathic restless legs syndrome (RLS) or Willis-Ekbom Disorder (WED).
* Subject has experienced RLS symptoms at night on 2 or more nights per week during the previous month.
* On typical dose and schedule of RLS medication (if any), subject typically experiences RLS symptoms on 2 or more nights per week.
* RLS symptoms are primarily in the evening and night.
* Subject owns the necessary equipment to respond to texts, phone calls, and video calls.
* Subject is 18 years of age or older when written informed consent is obtained.
* Subject has signed a valid, Institutional Review Board (IRB)-approved informed consent form, can understand the requirements of the study and instructions for device usage, and can converse in English.

Exclusion Criteria

* Subject has RLS that is known to be caused by another diagnosed condition.
* Subject has active implantable medical devices anywhere in the body (including pacemakers), or passive medical devices implanted in the leg.
* Subject has an uncontrolled sleep disorder other than RLS that significantly interferes with their sleep as determined by the trial director or physician.
* Subject has been diagnosed with one of the following conditions: Epilepsy or other seizure disorder, Cellulitis or open sores of the legs, Renal failure, Iron-Deficiency Anemia, Severe movement disorder symptoms (Parkinson's disease, Huntington's disease, dyskinesia, dystonia), Deep Vein Thrombosis, Stage 4-5 Chronic Kidney Disease, Multiple sclerosis, Current, active or acute or chronic infection other than viral upper respiratory tract infections, A malignancy within the past 5 years (not including basal or squamous cell skin cancer)
* Subject is on dialysis or anticipated to start dialysis while participating in the study
* Subject is allergic to electrode gel, polyurethane foam, or lycra.
* Subject has severe edema in lower legs.
* Subject has failed a nerve conduction study prescribed by a physician or has been diagnosed with severe peripheral neuropathy.
* During Visit 1, subject cannot notice the stimulation at the maximal dose or cannot tolerate the stimulation at the minimal effective dose
* Subject selects Statement 2 or is unable to decide which of the following two statements most closely describe their condition: Statement 1: My symptoms are best characterized by a strong or overwhelming urge to move my legs. Moving my legs often results in temporary relief of that urge. Statement 2: My symptoms are best characterized by involuntary leg spasms that happen at regular intervals. These leg spasms can wake me up in the middle of the night."
* Subject has significantly changed medication dose or schedule of antidepressants, sleep medications, or RLS medications within the past 30 days.
* Recent history of alcohol or recreational drug abuse (within the past 6 months).
* Subject has received an investigational drug or device within the last 30 days or is planning to receive an investigational device during the duration of the study.
* Subject has undergone a major surgery (excluding dental work) in the previous 30 days.
* Subject has another medical condition that may affect validity of the study or put the subject at risk as determined by the investigator.
* Subject is unable or unwilling to comply with study requirements

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No